The FDA has issued over 85 warning letters to GLP-1 telehealth companies since September 2025. The single most common violation category: misleading consumers about the FDA status of compounded medications.
The core issue is straightforward. Brand-name Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved. Compounded versions of the same active ingredients are not FDA-approved. They are legal under specific conditions — Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act — but they have not undergone the clinical trials, manufacturing inspections, and labeling reviews that FDA approval requires.
Patients have a right to know this before they buy. Most platforms make it surprisingly hard to find out.
The five disclosure failures we found
We audited the homepage, pricing page, FAQ, and checkout flow of 30 GLP-1 telehealth platforms in July 2026. We scored each on a simple question: Does the platform clearly and accurately communicate the FDA status of its compounded products before the patient enters payment information?
Failure 1: The word "FDA" used without context (14 of 30)
The most common failure. Phrases like "FDA-registered pharmacy," "uses FDA-approved active ingredients," or "FDA-compliant process" appear near product descriptions in ways that create a false impression of FDA approval for the compounded product itself.
Here's the precise distinction: the active ingredient (semaglutide) is FDA-approved in a specific formulation (Wegovy, Ozempic). The pharmacy may be FDA-registered (if it's a 503B facility) or state-licensed (if it's a 503A). But the compounded product you receive — the specific vial mixed at that specific pharmacy — is not FDA-approved. It is a different product, made by a different manufacturer, to a different specification.
Platforms that use "FDA" as an ambient trust signal without making this distinction clear are misleading consumers — and the FDA agrees, which is why it's been the basis for the majority of warning letters.
Failure 2: Disclosure buried in legal fine print (9 of 30)
Some platforms do disclose that their products are compounded and not FDA-approved — but only in the terms of service, in a footnote rendered in 10px gray text, or on a standalone "legal disclaimer" page that no reasonable consumer navigates to before checkout. This is technically compliant with the letter of some state pharmacy laws but fails the spirit of informed consent.
Failure 3: No disclosure at all (4 of 30)
Four platforms we audited made no mention of compounding, FDA status, or the distinction between their product and brand-name medications anywhere in the customer-facing flow. The patient could complete the entire journey from landing page to checkout to medication delivery without ever learning that the product is compounded.
Failure 4: Conflation with brand names (8 of 30)
Platforms that use "Ozempic," "Wegovy," "Mounjaro," or "Zepbound" in their ad copy, meta descriptions, or product names while actually selling compounded versions are engaging in trademark misuse and consumer deception simultaneously. This is the violation pattern most likely to draw both an FDA warning letter and a Novo Nordisk or Eli Lilly trademark action.
The Novo Nordisk lawsuit against Hims & Hers in early 2026 centered partly on this issue: Hims used the Ozempic and Wegovy brand names in marketing for compounded semaglutide products that Novo Nordisk did not manufacture or approve.
Failure 5: "Same exact molecule" claim without qualification (7 of 30)
The claim "same active ingredient as Wegovy/Ozempic" is technically accurate. The claim "same exact medication" is not. The active pharmaceutical ingredient may be the same, but the formulation, manufacturing process, quality testing, and delivery device are different. Platforms that equate "same molecule" with "same product" are making a claim the FDA has explicitly rejected in enforcement actions.
What good disclosure looks like
Three platforms in our audit scored perfectly. Their disclosures shared these characteristics:
Visible on the pricing page. Not buried in a footer. Not on a separate legal page. Directly adjacent to the product description and price, before the "add to cart" or "get started" button.
Plain language. Something close to: "This is a compounded medication containing [semaglutide/tirzepatide]. It is not FDA-approved. It is prepared by [pharmacy name], a [503A/503B] pharmacy licensed in [state]. It has not undergone the same testing as brand-name [Wegovy/Zepbound]."
Separated from marketing copy. The disclosure stands on its own — not embedded in a paragraph that starts with benefits and buries the regulatory status mid-sentence.
How to run this audit yourself
Pick your current GLP-1 telehealth provider. Go to their homepage. Search the page for the word "compounded." If it doesn't appear on the homepage, search the pricing page. If it doesn't appear there, search the FAQ. Track how many clicks it takes to find an explicit statement that the product is compounded and not FDA-approved.
Then check for brand name usage. Does the platform mention "Ozempic," "Wegovy," "Mounjaro," or "Zepbound" anywhere in its marketing? If so, does it clearly distinguish those brand-name products from the compounded versions it actually sells?
The platforms that disclose clearly are not at a competitive disadvantage — they're at a trust advantage. Patients who understand what they're buying are better-informed patients, and better-informed patients are more likely to stay on treatment, follow titration protocols, and report side effects appropriately. Transparency isn't just ethically correct. It's clinically better.
The next time the FDA issues a round of warning letters — and there will be a next time — the platforms that survive will be the ones that got disclosure right from the start. The ones that treated regulatory compliance as a marketing problem rather than a patient safety obligation will be on the receiving end.